DIAGNOSTICS

ZIVO Bioscience Announce Joining Russell Microcap® Index Membership

Zivo | June 28, 2022

ZIVO_Bio_science
ZIVO Bioscience, Inc. is a U.S.-based R&D company dedicated to the study, development and commercialization of natural nutritional compounds and bioactive molecules derived from proprietary algal strains, announced joining the Russell Microcap® Index (^RUMIC) as a result of the Russell indexes annual reconstitution in 2022.

Russell Microcap® Index membership that remains in place for a course of 12 months, means automatic inclusion in the appropriate value style and growth indexes. Membership for FTSE Russell's Russell indices is generally determined by market-capitalization rankings and style characteristics.

A leader in global indices, FTSE Russell, offers cutting-edge analytics, benchmarking, and data solutions to investors all over the world. FTSE Russell creates thousands of indexes to measure and benchmark markets and asset classes for over 70 nations, covering 98 percent of the world's investable markets.  It emphasizes on applying the strict industry norms in governance and index design and also embraces the IOSCO Principles.

We are pleased to be added to the Russell Microcap® Index this year. Our inclusion reflects continued interest in our stock along with long- and near-term growth expectations as we evolve and execute on our business strategy, I also look forward to expanding our stock’s exposure to a broader investor audience, including more institutional investors, as a result of ZIVO’s inclusion.”

John Payne, President and Chief Executive Officer of ZIVO Bioscience.

Russell indexes are increasingly used by institutional investors and investment managers for index funds for benchmarking active investment strategies. Approximately US$12 trillion in assets are benchmarked against Russell’s US indexes.

Spotlight

Community-based healthcare made great advances toward improving health within given geographies. Now, leading healthcare practitioners are moving beyond a place to think in terms of special groups of people, or populations, according to a new infographic by tork.

Spotlight

Community-based healthcare made great advances toward improving health within given geographies. Now, leading healthcare practitioners are moving beyond a place to think in terms of special groups of people, or populations, according to a new infographic by tork.

Related News

MEDTECH

BiOWiSH Technologies and SABIC Agri-Nutrients Company Announce Bio-Enhanced Mineral Fertilizer Collaboration

BiOWiSH Technologies, Inc. | July 22, 2022

BiOWiSH Technologies, Inc. and SABIC Agri-Nutrients Company announced the successful completion of a year-long technical evaluation of BiOWiSH® Crop Liquid technology coated on SABIC’s urea in nine countries across five continents and nine different crop types. BiOWiSH® Crop Liquid is a blend of proprietary microbial cultures that can be coated onto dry fertilizer or mixed with liquid fertilizers to create an enhanced efficiency fertilizer specifically designed to optimize yield potential and improve soil productivity. Featuring the company’s proprietary HoloGene 3™ technology, BiOWiSH® Crop Liquid creates a high-performance partnership between the plant and BiOWiSH microorganisms. The new alliance has a combined genetic profilethat enhances native microbial activity in the soil, promotes soil quality, and supports the plant’s natural ability to resist environmental stress. This optimizes crop yield potential by increasing nutrient availability and improving soil productivity and plant vigor. This unique mode of action, combined with the product’s industry-leading shelf life, is proven to achieve consistent desired results across a broad range of operating conditions, climates and environments – all at a low cost to farmers. “We are thrilled to confirm that SABIC AN Bio-Enhanced Urea powered by BiOWiSH® has performed extremely well in the field,” Munif Al-Munif, General Manager Agri-Nutrients Technology at SABIC AN “Our uniform, high-crushing strength urea combined with the superior technology of BiOWiSH® Crop Liquid delivers extended stability and consistent performance at a price per acre farmers can afford. In an industry challenged with high regulatory pressures and global food demand, we are excited to offer a sustainable product that safely increases crop production and generates higher profits for growers,” he added. The market launch of SABIC AN Enhanced Urea will initially be fulfilled through SABIC AN partners in select target countries while the teams work together to expand in other regions around the world. The launch follows extensive successful testing of the product across multiple international markets, including the United States. The Bio-Enhanced Urea, powered by BiOWiSH®, will be available at the same price as standard urea through the Archer-Daniels-Midland Company (ADM) and American Plant Food (APF) for a limited time in select areas. Customers can contact their ADM or APF representative for more details. In addition, SABIC AN and BiOWiSH have constructed a joint development platform designed to advance further customizations across a range of SABIC AN’s high-efficiency fertilizers. This partnership is the foundation for future products and other agronomic innovations. “We appreciate the close collaboration with SABIC AN’s team,” said BiOWiSH CEO Ian Edwards. “It is very exciting that a market-leading fertilizer company such as SABIC AN recognizes the importance of biologicals and is placing such high focus and energy on bringing Bio-Enhanced Mineral Fertilizer to customers across the globe. Together, we will work toward our shared goal of developing agricultural solutions that help farmers maximize productivity and increase income – while at the same time, improving environmental outcomes.” SABIC AN Bio-Enhanced Urea will be available to farmers in additional locations in the future, enabling growers to experience the benefits of BiOWiSH®-powered fertilizer. About BiOWiSH Technologies Headquartered in Cincinnati, Ohio, BiOWiSH Technologies, Inc. is a global provider of biotechnology solutions for the agriculture, aquaculture, and environmental management industries. As a leader in the agricultural market, we help farmers increase crop production sustainably, safely and cost effectively. Our revolutionary BiOWiSH® Crop Liquid can be coated onto dry fertilizer or mixed with liquid fertilizer to create an enhanced efficiency fertilizer that optimizes yield potential, expresses plant vigor and improves soil productivity across a broad range of operating conditions, climates and environments. By unifying nature and science, BiOWiSH reinvents the way food is grown. About SABIC Agri-Nutrients Company SABIC AN is a public joint stock company listed on the Saudi Stock Exchange where SABIC owns 50.1% with the remaining 49.9% being held by the private sector and the public. It is one of the leading global fertilizer producers. SABIC AN portfolio includes urea, ammonia, phosphate and other specialized products.

Read More

CELL AND GENE THERAPY

PINNACLE FERTILITY PARTNERS WITH IGENOMIX AS THEIR EXCLUSIVE GENETICS LABORATORY AND GENETIC COUNSELING PROVIDER

Igenomix | June 08, 2022

Pinnacle Fertility (Pinnacle), the fastest-growing network of physician-centered fertility practices representing more than seven clinics and 20 locations nationwide, has partnered with Igenomix as their exclusive preimplantation genetics testing (PGT) laboratory and provider for genetic counseling services. Continuing Pinnacle's commitment to collaborative medical leadership and patient-first care, this strategic partnership was the result of the Medical Council's collective determination and offers patients an increased opportunity to find success in their family-building journey. Our Medical Director Council extensively studied the science behind major genetic labs to determine which would provide us with the best possible data to make key decisions. Bringing Igenomix on as our exclusive genetics provider for Pinnacle Fertility clinics continues to ensure that we meet our single guiding principle which is to provide the best patient outcomes possible." Dr. Richard Marrs, Chief Medical Director for Pinnacle Fertility. With more than 15 years of experience, Igenomix is the global leader in reproductive genetics and focuses on quality, safety, and science to help healthcare professionals and patients detect genetic abnormalities before treatment, avoid implantation failure, and ensure patients achieve a healthy pregnancy. Pinnacle Fertility continues to set the standard in fertility care by bringing leading technology, integration and innovation to its suite of family building services. Partnerships with companies like Igenomix, who are committed though-leaders like we are, benefit our patients and those seeking to grow their families with the help world-class reproductive genetic testing and counseling services." Andrew Mintz, CEO at Pinnacle Fertility. PGT is an elective treatment option that can be used to identify embryos at risk of having a specific genetic or chromosomal condition and is available for patients at all fertility clinics within the Pinnacle network. Igenomix offers the most comprehensive portfolio of infertility treatments for genetics and was the first organization to launch non-invasive PGT-A services. Patients who choose to use PGT as part of their treatment plan receive complementary pre- and post-test genetic counseling to help guide and educate them on their options and results. Bringing Igenomix onboard is an exciting opportunity for our patients to seamlessly have access to genetic testing and counseling services, such as PGT at our fertility clinics, The genetic counselors are perfectly integrated into our programs and champion our patients' success like we do." Dr. Priya Maseelall from Reproductive Gynecology and Infertility Patients electing to use PGT, undergo in vitro fertilization (IVF) to create embryos, and then cells are removed from each embryo for genetic testing. Embryos with normal results are selected to be transferred into the uterus in hopes of achieving a pregnancy and delivering a child without a genetic condition. By utilizing PGT, genetic diseases can be prevented. In addition, studies have shown that PGT can not only improve success rates but also provide optimism and peace of mind during pregnancy and after birth. About Pinnacle Fertility Pinnacle Fertility is the nation's fastest-growing physician-centric fertility care platform, supporting high-performing fertility clinics and comprehensive fertility service providers nationwide. Under a united mission of fulfilling dreams by building families, Pinnacle clinics offer innovative technology and processes, compassionate patient care, and comprehensive fertility treatment services, ensuring families receive a high-touch experience on their path to parenthood. About Igenomix Igenomix is a global leader in reproductive genetic testing with laboratories in 23 countries and assisting hundreds of thousands of patients per year worldwide. As part of Vitrolife Group, the company is recognized for its R&D expertise and quality of service. In the US, Igenomix has proven to be the best-in-class when comes to credibility, consistency on their results, automatization of their laboratories and the most important, patient care.

Read More

MEDICAL

WuXi ATU and Wugen Announce Manufacturing Partnership to Expedite the Delivery of Novel Cell Cancer Immunotherapies

Wugen | June 16, 2022

WuXi Advanced Therapies (WuXi ATU), a global Contract Testing, Development and Manufacturing Organization (CTDMO), and Wugen Inc., a clinical-stage biotechnology company based in St. Louis and San Diego, today announced a partnership to produce Wugen's WU-NK-101, a novel immunotherapy that harnesses the power of memory natural killer (NK) cells to treat cancers. WuXi ATU will provide manufacturing and testing services for WU-NK-101 to enable the delivery of this innovative cell therapy product to cancer patients. Wugen aims to develop a pipeline of off-the-shelf cell therapy products to treat a broad range of hematological and solid tumor malignancies. As Wugen's first program from the company's proprietary MonetaTM platform, WU-NK-101 leverages the hyper-functional, long-lasting anti-tumor functionality of memory NK cells to manufacture next-generation, off-the-shelf cancer cell therapies at commercial scale. WU-NK-101 is currently in development to treat acute myelogenous leukemia (AML) and solid tumors. WuXi ATU's integrated CTDMO platform enables the development of WU-NK-101 by leveraging the company's Good Manufacturing Process (GMP) cell therapy manufacturing and testing capabilities to support regulatory filings and clinical trials. We are delighted to partner with WuXi ATU, With WuXi ATU's cell therapy manufacturing expertise, integrated GMP manufacturing and testing capabilities, we can keep advancing our allogeneic WU-NK-101 program into clinical trials and accelerate the timeline for delivering convenient, effective therapeutics to patients." Dr. Dan Kemp, President and Chief Executive Officer of Wugen. About WU-NK-101 WU-NK-101 is a novel immunotherapy harnessing the power of memory natural killer (NK) cells to treat liquid and solid tumors. Memory NK cells are hyper-functional, long-lasting immune cells that exhibit enhanced anti-tumor activity and a cytokine-induced memory-like (CIML) phenotype. This rare cell population has a superior phenotype, proliferation capacity, and metabolic fitness that makes it better suited for cancer therapy than other NK cell therapies. Wugen is applying its proprietary MonetaTM platform to advance WU-NK-101 as a commercially scalable, off-the-shelf cell therapy for cancer. WU-NK-101 is currently in development for acute myelogenous leukemia (AML) and solid tumors. About Wugen Wugen, Inc., is a clinical-stage biotechnology company developing the next generation of off-the-shelf memory natural killer (NK) and CAR-T cell therapies for cancer. Wugen is leveraging its proprietary MonetaTM platform and deep genomic engineering expertise to pioneer a new class of memory NK cell therapies with a cytokine-induced memory-like (CIML) phenotype, uniquely designed to treat hematological and solid tumor malignancies.

Read More